Category

UF Innovate | Tech Licensing

World Glaucoma Week: A Retina Specialist’s Guide to Recent Innovations in Glaucoma

Ophthalmologists and researchers have made great strides in the management of glaucoma. From implants and robotics to proper administration of eye drops, glaucoma is treated more effectively than ever. This article highlights some of the latest discoveries in glaucoma, including work by UF startup and Sid Martin Biotech company TearClear.

Medication Safety 2.0: Advances in Adherence Technology

A recently published review on emerging smart technology innovations in the health care sector suggests various advanced technologies and methods may now significantly improve medication adherence.1 Two significant advances have been the ability to measure medication adherence and safety issues with medication event monitoring systems (MEMS) and smart blister packs containing radio frequency identification technology.

Lacerta Therapeutics Expands Executive Leadership Team

UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.

Fitness App FitOn Raises $40M, Acquires Corporate Wellness Platform Peerfit

Digital fitness and wellness company FitOn has raised $40 million in Series C funding led by Delta-v Capital, the company announced on Tuesday. FitOn is also expanding its reach in wellness by acquiring Tampa-based corporate wellness platform Peerfit, a UF startup that incubated at UF Innovate | Accelerate at The Hub.

TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial

TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.